![Show Menu](styles/mobile-menu.png)
![Page Background](./../common/page-substrates/page1417.jpg)
G≥1: 89%
G≥2: 29%
G≥3: 4%
Vaginal morbidity overview
•
N=588 LACC within EMBRACE study
•
Prospective assessment of morbidity
(CTCAE 3) at baseline and regular
follow-ups (median 15 months)
•
Endpoints: vaginal stenosis, dryness,
mucositis, bleeding, fistula
Kirchheiner et al.
IJROBP 2014